Sirolimus in chronic allograft nephropathy

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Chronic allograft nephropathy (CAN) is a primary cause of late kidney transplant loss.
• Calcineurin inhibitor (CNI) nephrotoxicity is a significant contributor to CAN development.
• Sirolimus-based immunosuppression may allow for reduced or eliminated CNI use.

Purpose of the Study:

• To evaluate the efficacy and safety of sirolimus in kidney transplant recipients diagnosed with CAN.
• To assess the impact of sirolimus on graft function and patient outcomes in the context of CAN.

Main Methods:

• A prospective study involving 32 kidney transplant recipients with CAN treated with sirolimus.
• Patients received sirolimus alongside baseline immunosuppression (CNI, prednisone, mycophenolate mofetil).
• Graft biopsies were performed on 75% of patients prior to sirolimus initiation; follow-up averaged 8.5 months.

Main Results:

• Sirolimus demonstrated effectiveness in 50% of patients, with 9.4% showing improvement and 40.6% maintaining stable renal function.
• Efficacy was more pronounced in patients with serum creatinine < 3.0 mg/dL; effectiveness was limited in those with serum creatinine > 4.0 mg/dL.
• Common adverse events included hyperlipidemia (37.5%), anemia (25%), and diarrhea (21.8%); 12 patients discontinued therapy due to various complications.

Conclusions:

• Sirolimus is an effective treatment option for approximately 50% of kidney transplant recipients with CAN, particularly when serum creatinine is below 3.0 mg/dL.
• The use of sirolimus can lead to a reduction in CNI dosage in responders.
• Increased incidence of adverse events such as infection, diarrhea, and hyperlipidemia necessitates careful patient management and monitoring.